viable staphylococci when 0.5 ml of the inoculum was injected into the tail vein. At 1 hr after infection, the kidneys contained approximately 104 viable staphylococci per milliliter as determined by standard plate counts. A total of 40 mice were infected with each drug tested, so that groups of 10 mice could be withdrawn from the test and examined at intervals of 4, 11, 18, and 21 days after infection and medication.
Lysostaphin is an extracellular bacterial enzyme with highly specific antistaphylococcal activity primarily against coagulase-positive strains. Its in vitro antistaphylococcal activity has been studied extensively (2, 10) . Subsequently, comparisons were made in vitro with other antistaphylococcal antibiotics and semisynthetic penicillins (4, 12, 13) . All of these investigations substantiate the fact that lysostaphin is an extremely potent antistaphylococcal antibiotic which offers a novel and potentially useful approach to chemotherapy.
Schuhardt and Schindler (11) demonstrated that lysostaphin is effective in vivo against experimental staphylococcal peritonitis when given by either the intraperitoneal or subcutaneous routes. This observation was confirmed in our laboratory. Using other in vivo models, Harrison and Cropp (Can. J. Microbiol., in press) found that lysostaphin is capable of reducing the edema produced by a localized staphylococcal infection in the mouse leg, and that topical application of the antibiotic reduces the number of viable staphylococci in experimental rabbit ear infections.
Because of the high chemotherapeutic potency of this antibiotic in each of the experimental infection models that were tried, the studies reported here were undertaken to establish the chemotherapeutic potential of lysostaphin in staphylococcal renal abscesses produced experimentally in mice. Single intravenous doses of lysostaphin, ranging from 1.56 to 50 mg/kg, produced significantly lower bacterial populations in the kidney (Fig. 1) . Lysostaphin decreased the staphylococcal census by 5 log units as compared with the nonmedicated control kidneys. Similar observations have been made by W. Schaffner, M. A. Melly, and M. G. Koenig (Clin. Res. 14:343, 1966) using a comparable test model. At 0.5 mg/kg, elevated bacterial counts were observed at 4 and 11 days; however, the 18-and 21-day kidney populations were markedly decreased. Thus, a single dose of lysostaphin at this low level was apparently sufficient to control the staphylococcal population to the point where the normal host defense mechanisms could function.
High numbers of kidneys were cleared of the infection by the single-dose therapy of lysostaphin ( Table 2 ). The percentage of kidneys cleared ranged from 46 to 85% for lysostaphin, in contrast to 7 % for the nonmedicated control animals. Likewise, low mortality rates were obtained with all of the drug concentrations when lysostaphin was used for medication. The mortality rate of 55 to 80% for the nonmedicated control animals was lowered significantly by single-dose therapy of lysostaphin (0 to 15 %).
Single intravenous doses of lysostaphin as low as 1.56 mg/kg demonstrated a significant therapeutic effect, whereas numerous semisynthetic penicillins and other antibiotics administered in a similar manner at levels up to 25 mg/kg were essentially inactive. Only by the administration of a long-acting, depot form of penicillin (Bacillin) could results comparable to those observed with lysostaphin be obtained.
Best clearance of the renal infections was demonstrated by penicillins having benzyl or phenoxy side chains (penicillin G, ampicillin, propicillin) of the several penicillins tested. Penicillin G produced a low mortality rate, but it was not impressive in the total clearance or bacterial-census evaluation. Cephaloridine, the only cephalosporin tested, produced good clearance of the infection, but the kidney bacterial populations remained elevated until the terminal plating. The remaining semisynthetic penicillins kanamycin, vancomycin, and lincomycin were essentially inactive.
This study indicates that lysostaphin may have a role in systemic therapy of certain chronic staphylococcal lesions and their accompanying septicemias. Lysostaphin, because of its enzymatic mode of action (1), has the advantage of bringing about a rapid decrease in the staphylococcal titers, whereas most conventional antistaphylococcal antibiotics merely inhibit bacterial multiplication and, consequently, require much longer time periods to elicit marked decreases in staphylococcal counts in the blood. Lysostaphin has the added advantage of lysing coagulasepositive staphylococci readily regardless of their metabolic state, whereas all penicillin-like antibiotics inhibit only those bacteria which are actively multiplying and presumably building new cell wall structures.
From the data presented in this study, it appears that lysostaphin warrants further consideration as a potential antistaphylococcal agent for systemic use alone or as an adjunct to therapy with the semisynthetic penicillins.
